Desmoteplase

Drug Profile

Desmoteplase

Alternative Names: Bat-PA; Bat-tPA; Desmodus salivary plasminogen activator; DSPA; DSPA-A-1; DSPA-alpha-1; PN-01; rDSPA-alpha-1; SH-576; ZK-152387

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Bayer Schering Pharma
  • Developer Lundbeck A/S; PAION
  • Class Plasminogen activator enzymes; Recombinant proteins; Thrombolytics
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Myocardial infarction; Stroke; Thromboembolism

Most Recent Events

  • 17 Dec 2014 Discontinued - Phase-III for Stroke in USA, Hungary, United Kingdom, Sweden, South Africa, Norway, Mexico, Italy, Ireland, Finland, Denmark, Chile, Brazil, Belgium, Vietnam, Thailand, Taiwan, Switzerland, Spain, Poland, Philippines, the Netherlands, South Korea, India, Germany, France, Estonia, Austria, Japan, Singapore, Hong Kong, Australia and Canada (IV)
  • 25 Oct 2014 Additional efficacy and adverse events data from the phase III DIAS-3 trial in Stroke released by Lundbeck
  • 08 Oct 2014 Lundbeck A/S terminates the phase III DIAS-4 trial in Stroke in USA, Belgium, Brazil, Canada, Chile, Denmark, Estonia, Finland, Ireland, Italy, Mexico, Norway, South Africa, Spain, Sweden and United Kingdom (NCT00856661)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top